Management of Complex Pulmonary Vein Stenosis at Altitude Combining Comprehensive Percutaneous Interventional Treatment with Sirolimus, Pulmonary Hypertension Medications and Intraluminal Imaging with Optical Coherence Tomography

[1]  D. Ivy,et al.  Technical Feasibility on the Use of Optical Coherence Tomography in the Evaluation of Pediatric Pulmonary Venous Stenosis , 2022, Pediatric Cardiology.

[2]  M. Briones,et al.  Systemic Sirolimus Therapy for Infants and Children With Pulmonary Vein Stenosis. , 2021, Journal of the American College of Cardiology.

[3]  K. Gauvreau,et al.  Systemic Sirolimus to Prevent In-Stent Stenosis in Pediatric Pulmonary Vein Stenosis , 2019, Pediatric Cardiology.

[4]  E. Bacha,et al.  Outcomes and prognostic factors for postsurgical pulmonary vein stenosis in the current era , 2018, The Journal of thoracic and cardiovascular surgery.

[5]  S. Colan,et al.  Adjunct Targeted Biologic Inhibition Agents to Treat Aggressive Multivessel Intraluminal Pediatric Pulmonary Vein Stenosis , 2018, The Journal of pediatrics.

[6]  Christopher J. Petit,et al.  Reintervention Is Associated With Improved Survival in Pediatric Patients With Pulmonary Vein Stenosis. , 2017, JACC. Cardiovascular interventions.

[7]  K. Jenkins,et al.  Paucicellular Fibrointimal Proliferation Characterizes Pediatric Pulmonary Vein Stenosis: Clinicopathologic Analysis of 213 Samples From 97 Patients , 2017, The American journal of surgical pathology.

[8]  A. Iñíguez-Romo,et al.  Pulmonary vein stenosis: Etiology, diagnosis and management. , 2016, World journal of cardiology.

[9]  T. Fleming,et al.  Pediatric pulmonary hypertension. , 2013, Journal of the American College of Cardiology.

[10]  K. Gauvreau,et al.  Bilateral disease and early age at presentation are associated with shorter survival in patients with congenital heart disease and intraluminal pulmonary vein stenosis. , 2012, Congenital heart disease.

[11]  K. Gauvreau,et al.  Outcomes After Stent Implantation for the Treatment of Congenital and Postoperative Pulmonary Vein Stenosis in Children , 2012, Circulation. Cardiovascular interventions.

[12]  S. Colan,et al.  A prospective phase II trial of vinblastine and methotrexate in multivessel intraluminal pulmonary vein stenosis in infants and children. , 2011, Congenital heart disease.

[13]  R. Abraham,et al.  Mammalian target of rapamycin: discovery of rapamycin reveals a signaling pathway important for normal and cancer cell growth. , 2009, Seminars in oncology.

[14]  K. Maher,et al.  Pulmonary Vein Stenosis: Prematurity and Associated Conditions , 2008, Pediatrics.

[15]  L. Cantley,et al.  AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. , 2007, Archives of dermatology.

[16]  K. Inoki,et al.  mTOR pathway as a target in tissue hypertrophy. , 2007, Annual review of pharmacology and toxicology.

[17]  T. Doyle,et al.  Pulmonary vein stenosis. , 1995, Human pathology.

[18]  U. Christians,et al.  Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. , 1992, Drug metabolism and disposition: the biological fate of chemicals.

[19]  J. Dingemanse,et al.  Clinical Pharmacology of Bosentan, a Dual Endothelin Receptor Antagonist , 2004, Clinical pharmacokinetics.

[20]  Kun-Liang Guan,et al.  Dysregulation of the TSC-mTOR pathway in human disease , 2004, Nature Genetics.